학술논문
Biphasic decay of intact SHIV genomes following initiation of antiretroviral therapy complicates analysis of interventions targeting the reservoir.
Document Type
Academic Journal
Author
Kumar MR; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.; Fray EJ; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.; Bender AM; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.; Zitzmann C; Los Alamos National Laboratory, Los Alamos, NM 87545.; Ribeiro RM; Los Alamos National Laboratory, Los Alamos, NM 87545.; Perelson AS; Los Alamos National Laboratory, Los Alamos, NM 87545.; Barouch DH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215.; Siliciano JD; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.; Siliciano RF; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.; HHMI, Baltimore, MD 21205.
Source
Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE
Subject
Language
English
Abstract
The latent reservoir for HIV-1 in resting CD4 + T cells persists despite antiretroviral therapy (ART) and precludes cure. Reservoir-targeting interventions are evaluated in ART-treated macaques infected with simian immunodeficiency virus (SIV) or simian-human immunodeficiency virus (SHIV). Efficacy is determined by reservoir measurements before and after the intervention. However, most proviruses persisting in the setting of ART are defective. In addition, intact HIV-1 and SIV genomes undergo complex, multiphasic decay observable when new infection events are blocked by ART. Intervention-induced elimination of latently infected cells must be distinguished from natural decay. Here, we address these issues for SHIV. We describe an intact proviral DNA assay that allows digital counting of SHIV genomes lacking common fatal defects. We show that intact SHIV genomes in circulating CD4 + T cells undergo biphasic decay during the first year of ART, with a rapid first phase (t 1/2 = 30.1 d) and a slower second phase (t 1/2 = 8.1 mo) that is still more rapid that the slow decay observed in people with HIV-1 on long-term ART (t 1/2 = 3.7 y). In SHIV models, most interventions are tested during 2nd phase decay. Natural 2nd phase decay must be considered in evaluating interventions as most infected cells present at this time do not become part of the stable reservoir. In addition, for interventions tested during 2nd phase decay, a caveat is that the intervention may not be equally effective in people with HIV on long-term ART whose reservoirs are dominated by latently infected cells with a slower decay rate.